New video presentation by SensoDetect
New video presentation published to strengthen work with marketing and sales. The video is part of a larger marketing package that has been developed in accordance with the strategy that the company presented with objectives to reach sales of about 20 million in 2020.
The strategy's focus is to launch BERA 3.0 in the spring on two focus markets, Germany and the UK. Markets has about 150 million inhabitants and has like the the rest of the world about 20% mental illness among the population.
The markets have a high number of Psychiatrists per inhabitants, seen from a global perspective. With 18 and 19 psychiatrists per 100,000 inhabitants. They are pressed by an ever increasing mental illness, and demand for new and more effective tests seems very clear. Overall, there are about 30,000 psychiatrists who, along with other health care professionals handles about 30 million people with mental illness. The need for an efficient, simple and objective test would seem obvious and that is also why SensoDetect forecasts a very rapid growth in these markets. Our target audience is in addition to the 30,000 psychiatrists also psychologists, general practitioners and some specialist as more and more professionals are involved in investigations in the field of mental illness. SensoDetect, as previously announced, has also broadened its "intended use" so that more professionals can benefit from our technology in their investigations and thus help individuals to faster and more accurate help and diagnosis.
"To reach our goals we focus on finding partners and groups of clinics that can result in a faster deployment. We know that we can minimize the education and startup by targeting these groups since they are working closely together. The strategy and the goals set for 2020 is a challenge but also extremely inspiring and we are very focused!", says CEO, Johan Olson, SensoDetect Ab (publ.)
CEO, SensoDetect Aktiebolag (publ)
Phone + 46 46-15 12 73
SensoDetect belyser genom patenterad utrustning hjärnstammens reaktioner på ljudstimuli i syfte att ge sjukvården tydliga avvikelser och mönster för användning inom främst psykiatrin. Målet är att öka effektiviteten inom psykiatrin och därmed nyttan för sjukvården, samhället, patienter och anhöriga. SensoDetect är sprunget ur mångårig forskning vid Kliniskt psykoakustiskt laboratorium i Lund. Bolagets aktie är listad på AktieTorget.
Improve the lives of people with mental illness
Making ABR profiling tests with SensoDetect technology an integral part of setting diagnosis for mental illness
Our Value Proposition:
SensoDetect provides a complete audiogram for the brainstem, helping health care professional to set psychiatric diagnoses objectively and
cost effectively. This unique offering improves patients’ quality of life and reduces the economic impact on the health care system and society